|Marine pharmacology in 2005-6: Antitumour and cytotoxic compounds|
|Mayer, A.M.S.; Gustafson, K.R. (2008). Marine pharmacology in 2005-6: Antitumour and cytotoxic compounds Eur. J. Cancer (1990) 44(16): 2357-2387. dx.doi.org/10.1016/j.ejca.2008.07.001|
|In: European Journal of Cancer. Pergamon: Oxford. ISSN 0959-8049, meer|
Marine; antitumor; drugs; agents; antineoplastic; cancer; chemotherapy; pharmacology; review; screening
During 2005 and 2006, marine pharmacology research directed towards the discovery and development of novel antitumour agents was reported in 171 peer-reviewed articles. The purpose of this article is to present a structured review of the antitumour and cytotoxic properties of 136 marine natural products, many of which are novel compounds that belong to diverse structural classes, including polyketides, terpenes, steroids, and peptides. The organisms yielding these bioactive marine compounds included invertebrate animals, algae, fungi and bacteria. Antitumour pharmacological studies were conducted with 42 structurally defined marine natural products in a number of experimental and clinical models which further defined their mechanisms of action. Particularly potent in vitro cytotoxicity data generated with murine and human tumour cell lines was reported for 94 novel marine chemicals with as yet undetermined mechanisms of action. Noteworthy is the fact that marine anticancer research was sustained by a global collaborative effort, involving researchers from Australia, Belgium, Benin, Brazil, Canada, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, the Netherlands, New Zealand, Panama, the Philippines, Slovenia, South Korea, Spain, Sweden, Taiwan, Thailand, United Kingdom, and the United States. Finally, this 2005-6 overview of the marine pharmacology literature highlights the fact that the discovery of novel marine antitumour agents continued at the same active pace as during 1998-2004.